Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.

[1]  D. Katsaros,et al.  Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[2]  T. Jobo,et al.  Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. , 2013, The Lancet. Oncology.

[3]  I. Vergote,et al.  Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer. , 2013, European journal of cancer.

[4]  J. Rauh-Hain,et al.  The Role of Intraoperative Radiation Therapy in the Management of Recurrent and Locally Advanced Gynecologic Cancers , 2013, International Journal of Gynecologic Cancer.

[5]  E. Eisenhauer,et al.  First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  A. Khrunin,et al.  Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. , 2012, Pharmacogenomics.

[7]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[8]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[9]  C. Figdor,et al.  Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. , 2011, The Journal of clinical investigation.

[10]  E. Eisenhauer,et al.  Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. , 2010, Journal of the National Cancer Institute.

[11]  B. Weber,et al.  Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  V. Gebski,et al.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[14]  D. Alberts,et al.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Kimmig,et al.  Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Young,et al.  Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? , 2004, Anti-cancer drugs.

[17]  M. Piccart,et al.  Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[18]  T. Bauknecht,et al.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. , 2003, Journal of the National Cancer Institute.

[19]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Y. Saga,et al.  A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer. , 2003, Oncology reports.

[21]  J Verweij,et al.  Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. , 2002, European Journal of Cancer.

[22]  J. Verweij,et al.  Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer , 2002, British Journal of Cancer.

[23]  J. Verweij,et al.  Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer , 2001, British Journal of Cancer.

[24]  M. Burg.  Advanced ovarian cancer , 2001, Current treatment options in oncology.

[25]  H. V. van Houwelingen,et al.  Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.

[27]  K. Nielsen,et al.  A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). , 1993, Gynecologic oncology.

[28]  S. Rubin,et al.  Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. , 1992, Gynecologic oncology.

[29]  L. Norton.  A Gompertzian model of human breast cancer growth. , 1988, Cancer research.

[30]  L. Norton,et al.  Predicting the course of Gompertzian growth , 1976, Nature.

[31]  G. W. Snedecor.  STATISTICAL METHODS , 1967 .

[32]  Chih-Long Chang,et al.  Dose-dense chemotherapy improves mechanisms of antitumor immune response. , 2013, Cancer research.

[33]  下山正徳.  National Cancer Institute-Common Toxicity Criteria (NCI-CTC Version 2.0, Jan. 30, 1998)-日本語訳JCOG版- , 1999 .

[34]  A. Heintz,et al.  Advanced ovarian cancer. An overview of multi-variate analyses of prognostic variables with special reference to the role of cytoreductive surgery. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.